Emergency care in pediatric septic shock

Pediatric Emergency Care

Volumn 20, Issue 9, 2004, Pages 617-624

  Maar, Stefan P ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b NONE   (United States)

Author keywords

Children 0 to 18 years; Emergency care; Pediatric emergencies; Septic shock

Indexed keywords

ACTIVATED PROTEIN C; ADRENALIN; ANTIBIOTIC AGENT; CEFTRIAXONE; DOBUTAMINE; DOPAMINE; FRESH FROZEN PLASMA; HYDROCORTISONE; MILRINONE; NITROPRUSSIDE SODIUM; NORADRENALIN; STEROID; VANCOMYCIN;

BACTEREMIA; EMERGENCY; ERYTHROCYTE CONCENTRATE; FIRST AID; FLUID THERAPY; HUMAN; INCIDENCE; MULTIPLE ORGAN FAILURE; PATHOPHYSIOLOGY; PEDIATRICS; PRACTICE GUIDELINE; REVIEW; SEPSIS; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

CHILD; EMERGENCY TREATMENT; HUMANS; SHOCK, SEPTIC;

EID: 4544260130     PISSN: 07495161     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pec.0000139747.61838.49     Document Type: Review

References (42)

1. Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med. 2003;167:695-701.
2. Carcillo JA. Pediatric septic shock and multiple organ failure. Crit Care Clin. 2003;19:413-440.
3. Kutko MC, Calarco MP, Flaherty MB, et al. Mortality rates in pediatric septic shock with and without multiple organ system failure. Pediatr Crit Care Med. 2003;4:333-337.
4. Tabbutt S. Heart failure in pediatric septic shock: utilizing inotropic support. Crit Care Med. 2001;29(suppl):S231-S236.
5. Vincent JL, Abraham E, Annane D, et al. Reducing mortality in sepsis: new directions. Crit Care. 2002;6:S1-S18.
6. Carcillo JA, Fields AI, Task Force Committee Members. Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock. Crit Care Med. 2002;30:1365-1378.
7. Kleinpell R. Advances in treating patients with severe sepsis: role of drotrecogin alfa (activated). Crit Care Nurse. 2003;22:16-29.
8. Eli Lilly and Company. Pathophysiology. Sepsis.com site. Available at: http://www.sepsis.com/pathogenesis.jsp. Accessed April 26, 2004.
9. Dalton HJ. Recombinant activated protein C in pediatric sepsis. Concise Rev Pediatr Infect Dis. 2003;22:743-745.
10. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for sever sepsis. N Engl J Med. 2001;344:699-709.
11. Nimah M, Brilli RJ. Coagulation dysfunction in sepsis and multiple organ system failure. Crit Care Clin. 2003;19:441-458.
12. Grocott-Mason RM, Shah AM. Cardiac dysfunction in sepsis: new theories and clinical implications. Intensive Care Med. 1998;24:286-295.
13. Rivers E, Nguyen B, Havstad S. et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368-1377.
14. Han YY, Carcillo JA, Dragotta MA, et al. Early reversal of pediatric-neonatal septic shock by community physicians is associated with improved outcomes. Pediatrics. 2003;112:793-799.
15. Butt W. Septic shock. Pediatr Clin North Am. 2001;48:601-625.
16. O'Brien JM, Abraham E. New approaches to the treatment of sepsis. Clin Chest Med. 2003;24:521-548.
17. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858-873.
18. Fein AM, Calalang-Colucci MG. Acute lung injury and acute respiratory distress syndrome in sepsis and septic shock. Crit Care Clin. 2000;16:289-317.
19. Schleinen CL, Osmond MH, Hickey R, et al. Postresuscitation management. Ann Emerg Med. 2001;37:S182-S195.
20. Levy B, Bollaert PE, Charpentier C, et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Med. 1997;23:282-287.
21. Vincent JL, Bruzzi de Carvalho F, De Backer D. Management of septic shock. Ann Med. 2002;34:606-613.
22. Ceneviva G, Paschall A, Maffei F, et al. Hemodynamic support in fluid-refractory pediatric septic shock. Pediatrics. 1998;102:e19.
23. Hatherill M, Tibby SM, Hilliard T, et al. Adrenal insufficiency in septic shock. Arch Dis Child. 1999;80:51-55.
24. Min M, Aye M, Shwe TN, et al. Hydrocortisone in the management of dengue shock syndrome. Southeast Asian J Trop Med Public Health. 1975;6:573-579.
25. Sumarmo, Talogo W, Asrin A, et al. Failure of hydrocortisone to affect outcome in dengue shock syndrome. Pediatrics. 1982;69:45-49.
26. Bollaert PE, Charpentier C, Lvey B, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med. 1998;26:645-650.
27. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, doubleb-blind, single-center study. Crit Care Med. 1999;27:723-732.
28. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288:862-871.
29. Keh D, Boehnke T, Weber-Cartens S, et al. Immunologic and hemodynamic effect of "low dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med. 2003;167:512-520.
30. Ibsen LM, Bratton SL, Goldstein B. Decision points in the management of pediatric septic shock. Semin Pediatr Infect Dis. 2000;11:43-52.
31. Cardenas-Rivero N, Chernow B, Stoiko MA, et al. Hypoglycemia in critically ill children. J Pediatr. 1989;114:946-951.
32. Van den Berghe G, Wouters P, Weekers F. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359-1367.
33. Das UN. Insulin: an endogenous cardioprotector. Curr Opin Crit Care. 2003;9:375-383.
34. Warren HS, Suffredini AF, Eichacker PQ, et al. Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med. 2002;347:1027-1030.
35. Barton P, Kalil AC, Nadel S, et al. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics. 2004;113:7-17.
36. Giroir BP. Recombinant human activated protein C for the treatment of severe sepsis: is there a role in pediatrics? Curr Opin Pediatr. 2003;15:92-96.
37. Tugrul S, Ozcan PE, Akinci O, et al. The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis. Crit Care. 2002;6:357-362.
38. Derkx B, Wittes J, McCloskey R, et al. Randomized placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. Clin Infect Dis. 1999;28:770-777.
39. Dellinger RP. Inflammation and coagulation: implications for the septic patient. Clin Infect Dis. 2003;36:1259-1265.
40. Warren BL, Eid A, Singer P, et al. High dose antithrombin III in severe sepsis. JAMA. 2001;286:1869-1878.
41. Burns JP. Septic shock in the pediatric patient: pathogenesis and novel treatments. Pediatr Emerg Care. 2003;19:112-115.
42. Busund R, Koukline V, Utrobin U, et al. Plasmapheresis in severe sepsis and septic shock: a prospective, randomized, controlled trial. Intensive Care Med. 2002;28:1434-1439.